The Cost-Effectiveness of Saxagliptin Versus NPH Insulin When Used in Combination with Other Oral Antidiabetes Agents in the Treatment of Type 2 Diabetes Mellitus in Poland
| العنوان: | The Cost-Effectiveness of Saxagliptin Versus NPH Insulin When Used in Combination with Other Oral Antidiabetes Agents in the Treatment of Type 2 Diabetes Mellitus in Poland |
|---|---|
| المؤلفون: | Katarzyna Kolasa, Cezary Sciborski, Phil McEwan, Leszek Czupryniak, Isabelle Duprat Lomon, Władysław Grzeszczak |
| المصدر: | Diabetes Technology & Therapeutics. 14:65-73 |
| بيانات النشر: | Mary Ann Liebert Inc, 2012. |
| سنة النشر: | 2012 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Cost effectiveness, Cost-Benefit Analysis, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Insulin, Isophane, Adamantane, NPH insulin, Type 2 diabetes, Saxagliptin, chemistry.chemical_compound, Endocrinology, Diabetes mellitus, Internal medicine, medicine, Humans, Hypoglycemic Agents, Glycated Hemoglobin, Dipeptidyl-Peptidase IV Inhibitors, business.industry, Insulin, Type 2 Diabetes Mellitus, Dipeptides, Middle Aged, medicine.disease, Metformin, Medical Laboratory Technology, Models, Economic, Sulfonylurea Compounds, Diabetes Mellitus, Type 2, chemistry, Drug Therapy, Combination, Female, Poland, Quality-Adjusted Life Years, business, medicine.drug |
| الوصف: | This study compared the health and economic benefits of saxagliptin versus insulin as second-line therapy with either metformin (MET) or sulfonylurea (SU) after failure of the respective monotherapies for patients with type 2 diabetes in Poland.The cost-effectiveness was assessed using a previously published diabetes model. Disease progression, utilities, and effects of changes in glycosylated hemoglobin (HbA1c), weight, and hypoglycemic events were taken from published studies, and Polish sources were used where possible.MET + saxagliptin reduced severe hypoglycemic complications and weight versus MET + insulin, with an incremental benefit of 0.13 quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio (ICER) of 27,454 Polish zloty (PLN) ($9,966 U.S.) per QALY gained. SU + saxagliptin showed an incremental benefit of 0.14 QALYs and ICER of 24,663 PLN ($8,953 U.S.) per QALY gained versus SU + insulin, with reduced incidence of symptomatic and severe hypoglycemias. Results were most sensitive to disutilities associated with weight gain, hypoglycemia, injection fear, HbA1c changes, threshold for switching treatment, and patients' age. Results were robust to various model assumptions and inputs. Using a willingness-to-pay threshold of 100,000 PLN ($36,300 U.S.) per QALY gained, the probability that saxagliptin is cost-effective in these analyses was 74% (MET) and 76% (SU).Saxagliptin in combination with MET or SU is likely to represent a cost-effective treatment option in Polish patients with type 2 diabetes failing first-line treatment. |
| تدمد: | 1557-8593 1520-9156 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aabf8fda99080d04d76581547510f69Test https://doi.org/10.1089/dia.2011.0092Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....2aabf8fda99080d04d76581547510f69 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15578593 15209156 |
|---|